Surgery, octreotide, temozolomide, bevacizumab, radiotherapy and pegvisomant treatment of an AIP mutation positive child

    The Journal of clinical endocrinology and metabolism, 2019.

    Cited by: 0|Bibtex|Views0|Links
    WOS

    Abstract:

    Multimodal treatment with surgery, octreotide-LAR, radiotherapy, temozolomide, bevacizumab and pegvisomant can control genetically driven aggressive childhood-onset somatotrophinomas.

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments